drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
Intravenous monoclonal antibody targeting SLAMF7/CS1 that activates NK cells and mediates ADCC against myeloma cells.
nci_thesaurus_concept_id
C66982
nci_thesaurus_preferred_term
Elotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.
drug_mesh_term
Elotuzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
General immune activator
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody that binds SLAMF7/CS1 on myeloma and NK cells, activating NK cells and promoting Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) to kill SLAMF7-positive myeloma cells.
drug_name
Elotuzumab
nct_id_drug_ref
NCT05730036